Esophageal & Gastric Cancer
FDG-PET/CT for staging, neoadjuvant response, and restaging of esophagogastric cancer
Quick Answer
FDG-PET/CT in esophageal and esophagogastric-junction (EGJ) cancer is used mainly for staging (detecting distant metastases and unsuspected nodes that upstage disease and avoid futile esophagectomy) and for assessing response to neoadjuvant chemo/chemoradiation — where early metabolic response predicts outcome and can guide therapy (the MUNICON concept). It is not a T-staging tool (that is endoscopic ultrasound) and has key false-negative histologies: signet-ring, mucinous, and diffuse (linitis plastica) gastric cancers are often FDG-low, and physiologic gastric/EGJ uptake plus post-radiation esophagitis are confounders.
Background
Esophageal cancer is squamous (mid/upper, tobacco/alcohol) or adenocarcinoma (lower/EGJ, Barrett/reflux/obesity); gastric cancer is predominantly adenocarcinoma. Management hinges on resectability and distant spread — and a substantial fraction of patients have occult M1 disease at presentation, which is exactly where whole-body FDG changes the plan.
Clinical Role by Setting
- Initial staging: after endoscopy/biopsy and CT, FDG-PET/CT detects distant metastases and non-regional nodes, upstaging ~10–20% and sparing futile surgery; it also flags synchronous second primaries.
- Neoadjuvant response: a fall in SUV after induction chemo/chemoradiation correlates with pathologic response and survival; metabolic non-responders may be switched (MUNICON used early PET to change chemotherapy in EGJ adenocarcinoma).
- Restaging / suspected recurrence: localizes recurrence and distant disease when markers/symptoms rise.
What FDG-PET Does NOT Do Well
- T-stage / depth of invasion and regional peri-tumoral nodes → endoscopic ultrasound (EUS).
- Early gastric cancer and FDG-low histologies (signet-ring/mucinous/diffuse) — often invisible.
- Peritoneal carcinomatosis may be underestimated → staging laparoscopy for gastric cancer.
Interpretation & Pitfalls
- Physiologic gastric wall and EGJ uptake is common — distend/position and correlate with endoscopy; a lax GEJ or reflux esophagitis causes benign uptake.
- Post-chemoradiation esophagitis/inflammation raises SUV and can mimic residual tumor — timing (allow ~6 weeks) matters.
- FDG-low histologies → a normal PET does not exclude disease; correlate with endoscopy/EUS and consider FAPI in research settings.
Reporting Checklist
- State primary avidity, nodal (regional vs non-regional/distant), and distant metastatic findings; explicitly comment on upstaging relevance to surgical candidacy.
- For response, report SUV change against baseline with matched technique.
- Caveat FDG-low histology and physiologic/inflammatory uptake.
Differential / Confounders
Physiologic gastric/EGJ uptake, reflux esophagitis, post-radiation inflammation, benign nodes, brown fat (neck/mediastinum), and FDG-low tumor giving a false-negative.
Board facts at a glance
Match the staging question to the right tool — the classic board discrimination:
| Question | Best tool | Note |
|---|---|---|
| T-stage (depth of invasion) | EUS | PET does not assess T or peritumoral regional nodes |
| N-stage (non-regional nodes) | FDG-PET/CT | Upstages ~10–20% |
| M-stage (distant) | FDG-PET/CT | Detects occult M1 → avoid futile esophagectomy |
| Peritoneal disease | Staging laparoscopy | PET underestimates |
| Neoadjuvant response | FDG-PET (SUV fall) | MUNICON concept; wait ~6 wk after chemoradiation |
| FDG-low histologies | (PET unreliable) | Signet-ring, mucinous, diffuse/linitis plastica |
Board Pearls
FDG-PET/CT in esophagogastric cancer is chiefly for staging — detecting distant metastases/non-regional nodes that upstage disease and avoid futile esophagectomy — and for neoadjuvant response (a fall in SUV predicts pathologic response/survival; MUNICON used early PET to switch non-responders). It is not a T-staging tool — that is EUS.
Key false negatives: signet-ring, mucinous, and diffuse (linitis plastica) gastric cancers are often FDG-low, so a normal PET doesn't exclude disease. Physiologic gastric/EGJ uptake and post-radiation esophagitis are the main false positives — allow ~6 weeks after chemoradiation before restaging.
Peritoneal disease is underestimated (→ staging laparoscopy in gastric cancer), and early gastric cancer is usually PET-occult. Squamous (upper/mid, tobacco-alcohol) vs adenocarcinoma (lower/EGJ, Barrett/reflux) differ in epidemiology but share the same PET staging role; watch synchronous second primaries in squamous disease.
Related Pages
- Tracer: FDG; reference: oncology response criteria (RECIST/PERCIST); related: colorectal cancer, FDG-PET preparation & physiologic uptake.
Figure / Diagram Suggestions
- A staging-changes-management schematic (occult M1 → avoid esophagectomy).
- A metabolic-responder vs non-responder neoadjuvant SUV plot (MUNICON concept).
- An FDG-low histology caveat panel (signet-ring/mucinous/diffuse).
Self-Check
Q1. What is the main value of FDG-PET/CT in staging esophagogastric cancer?
Answer: Detecting distant metastases and non-regional nodes that upstage disease and avoid futile esophagectomy (and flag synchronous second primaries).
Q2. Which gastric histologies are typically FDG-low, and what's the implication?
Answer: Signet-ring, mucinous, and diffuse (linitis plastica) — a normal FDG-PET does not exclude disease; correlate with endoscopy/EUS.
Q3. What does FDG-PET add in the neoadjuvant setting (MUNICON concept)?
Answer: An early fall in SUV predicts pathologic response and survival; metabolic non-responders can be switched to a different strategy.
Q4. Why wait ~6 weeks after chemoradiation before restaging with FDG-PET?
Answer: Post-radiation esophagitis/inflammation raises SUV and mimics residual tumor — timing reduces false positives.
Evidence & sources
https://nuc.med/esophagogastric-cancer/ Report an issue